The number of preliminary or unsubstantiated treatments or risk factors for the coronavirus is increasing. Here's one reason why.
In our institutions of higher education and our research labs, scholars first produce, then buy back, their own content. With the costs rising and access restricted, something's got to give.
The traditional mode of publishing scientific research faces much criticism – primarily for being too slow and sometimes shoddily done. Maybe fewer publications of higher quality is the way forward.